If you take the Guggenheim report at face value, that the re-rating is essentially because of the likelihood of trofinetide being approved, then by far the better option would be to buy NEU.
I wonder whether the analyst points that out to his clients?
Share Price, page-60
-
- There are more pages in this discussion • 11,804 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.67 |
Change
0.060(0.44%) |
Mkt cap ! $1.763B | |||
| Open | High | Low | Value | Volume |
| $13.60 | $13.85 | $13.51 | $1.032M | 75.17K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 6 | $13.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.68 | 412 | 6 |
View Market Depth
| Last trade - 12.01pm 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |